 EMERYVILLE, Calif., Nov. 11, 2020 GLOBE NEWSWIRE -- XOMA Corporation Nasdaq: XOMA XOMA or the Company today announced it has earned a 1 million milestone payment from Agenus Inc. NASDAQ: AGEN related to Mercks advancement of MK-4830 into a Phase 2 study in patients with advanced non-small cell lung cancer NSCLC previously treated with anti-programmed cell death receptor ligand 1 PD-L1 therapy. MK-4830 is part of XOMAs first transaction under its royalty and milestone aggregator business model in which the Company acquired a royalty interest in seven milestone and royalty-bearing licenses Agenus held with Merck and Incyte for 15 million. 